Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P08908 (5-HT1A)
 5,574 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A method to measure various aspects of exploratory behavior was further characterized using standard pharmacological treatments known to induce anxiety, or anxiolysis, or locomotor activation. FG 7142, an anxiogenic beta-carboline, induced a dose-dependent reduction in the rat exploratory behavior. A single FG 7142 (20 mg/kg) treatment before behavioral testing had a carry-over effect on rats' behavioral performance on the two subsequent days. When FG 7142 (20 mg/kg) was administered during five consecutive days before behavioral testing, its anxiogenic-like effect first deepened, but waned off by the fifth session. Diazepam at the dose of 0.5 mg/kg had no effect of its own, but blocked the anxiogenic-like effect of FG 7142 (10 mg/kg) treatment. At a higher dose (1 mg/kg), diazepam treatment reduced exploratory behavior, but this effect was not carried over to the drug-free sessions on the subsequent day. Buspirone and gepirone (both 1 mg/kg), the 5-HT1A receptor agonists, had no effect. D-Amphetamine, a locomotion-enhancing drug which has anxiogenic-like properties in several tests of exploratory behavior, increased the activity of rats at the dose of 0.5 mg/kg, but at the dose of 1 mg/kg the only effect was a reduction in the number of rearings: this effect was not carried over to the subsequent retest. On the basis of the results described in this article and elsewhere, we suggest that this technique can be useful for separating a true anxiogenic drug from other compounds which influence exploratory activity.
 ...
PMID:Characterization of rat exploratory behavior using the exploration box test. 958 Apr 70

Several compounds were tested on the differential-reinforcement-of-low-rate 72-sec (DRL 72-sec) schedule, a behavioral screen to determine putative antidepressants; these compounds were evaluated in two outbred stocks of rats, Harlan and Holtzman Sprague-Dawley rats. A dose-response determination for the tricyclic antidepressants, imipramine and desipramine, the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor, fluoxetine, the 5-HT2 receptor antagonist, ketanserin, the 5-HT1A receptor agonist, (+/-)8-hydroxy-di-propylamino tetralin (8-OH-DPAT) and the dopamine releasing compound, amphetamine, were assessed in both rat stocks. The two stocks of rats differed in their baseline performance on the DRL 72-sec schedule. The Harlan rats had a higher reinforcement rate and a lower response rate than the Holtzman rats. In Holtzman, but not in Harlan rats, imipramine, ketanserin, fluoxetine and 8-OH-DPAT increased reinforcement rate and decreased response rate on the DRL 72-sec schedule, confirming previous studies. However, desipramine was the only drug to increase reinforcement rate and decrease response rate in both Holtzman and Harlan rats; in Harlan rats, drugs that primarily act upon the 5-HT system, imipramine, ketanserin, fluoxetine and 8-OH-DPAT, disrupted the DRL 72-sec performance and did not increase the number of reinforcements over baseline as was seen in Holtzman rats. Amphetamine disrupted DRL 72-sec performance in both Holtzman and Harlan rats in a similar manner. The hypothermic response to 8-OH-DPAT was also assessed in the two stocks of rats; Holtzman rats had a smaller decrease in core body temperature than Harlan rats. The observed behavioral and pharmacological differences between Holtzman and Harlan rat stocks may be genetically and/or environmentally mediated.
 ...
PMID:Holtzman and Harlan Sprague-Dawley rats: differences in DRL 72-sec performance and 8-hydroxy-di-propylamino tetralin-induced hypothermia. 969 29